Research ArticleArticle
Therapeutic Neuroprotection by an Engineered Neurotrophin that Selectively Activates Tropomyosin Receptor Kinase (Trk) Family Neurotrophin Receptors but Not the p75 Neurotrophin Receptor
Fouad Brahimi, Alba Galan, Sairey Siegel, Stephanie Szobota, Marinko V. Sarunic, Alan C. Foster and H. Uri Saragovi
Molecular Pharmacology November 2021, 100 (5) 491-501; DOI: https://doi.org/10.1124/molpharm.121.000301
Fouad Brahimi
Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon Fraser University, British Columbia, Canada (M.V.S.)
Alba Galan
Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon Fraser University, British Columbia, Canada (M.V.S.)
Sairey Siegel
Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon Fraser University, British Columbia, Canada (M.V.S.)
Stephanie Szobota
Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon Fraser University, British Columbia, Canada (M.V.S.)
Marinko V. Sarunic
Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon Fraser University, British Columbia, Canada (M.V.S.)
Alan C. Foster
Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon Fraser University, British Columbia, Canada (M.V.S.)
H. Uri Saragovi
Lady Davis Institute-Jewish General Hospital (F.B., A.G., H.U.S.), Pharmacology and Therapeutics (H.U.S.), and Ophthalmology and Vision Science (H.U.S.), McGill University, Montreal, Quebec, Canada; Otonomy, Inc., San Diego, California (S.Si., S.Sz., A.C.F.); and School of Engineering Science, Simon Fraser University, British Columbia, Canada (M.V.S.)

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
In Vivo Efficacy of a Pan-Trk Agonist with Low p75 Affinity
Fouad Brahimi, Alba Galan, Sairey Siegel, Stephanie Szobota, Marinko V. Sarunic, Alan C. Foster and H. Uri Saragovi
Molecular Pharmacology November 1, 2021, 100 (5) 491-501; DOI: https://doi.org/10.1124/molpharm.121.000301
Research ArticleArticle
In Vivo Efficacy of a Pan-Trk Agonist with Low p75 Affinity
Fouad Brahimi, Alba Galan, Sairey Siegel, Stephanie Szobota, Marinko V. Sarunic, Alan C. Foster and H. Uri Saragovi
Molecular Pharmacology November 1, 2021, 100 (5) 491-501; DOI: https://doi.org/10.1124/molpharm.121.000301
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement